On April 15, Astellas Pharmaceuticals (China) Co., Ltd. (hereinafter referred to as "Astellas") successfully completed the first batch of domestic customs clearance of XOSPATA® (Gilteritinib Fumarate Tablets), the global innovative hematocumoral cancer drug, in Shanghai Customs. With the joint efforts of Qingdao Baheal Medical INC. (hereinafter referred to as " Baheal Medical "), after customs clearance, XOSPATA® quickly entered 36 DTP pharmacies in 26 provinces and cities in China.

Meanwhile, on the second day after customs clearance, the first national prescription of XOSPATA® landed in Beijing Baheal Health Pharmacy, and the first batch of patients successfully purchased the medicine. XOSPATA® is the first FLT3 inhibitor approved by the U.S. Food and Drug Administration (FDA) and National Medical Products Administration (NMPA) for the treatment of refractory or relapsed acute myeloid leukemia (AML) .

In December 2020, Astellas and Baheal Medical reached a cooperation to jointly promote the entry of XOSPATA® into the Chinese market, filling the domestic market for FLT3-mutated refractory or relapsed acute myeloid leukemia (AML) patients with no approved targeted drugs Available gaps to bring new treatment options to adult patients with AML.

In February 2021,XOSPATA® was approved for marketing in China. After the approval, Baheal Medical and Astellas immediately started the overall deployment of import matters. With the support of Shanghai Customs and Shanghai Food and Drug Inspection Institute, the whole process of import of innovative drugs such as XOSPATA ® qualification examination, product code allocation, drug inspection and customs clearance of imported drugs was quickly realized. After customs clearance, the first batch of XOSPATA® was delivered to 36 DTP pharmacies in 26 provinces and cities within 24 hours, achieving the shortest drug delivery time and setting a new record for drug delivery.

Just the next day after customs clearance, the first domestic prescription of XOSPATA® landed in Beijing Baheal Health Pharmacy dongdan North Street store. As a professional smart pharmacy under Baheal Medical, Baheal Health Pharmacy is a new model with pharmacy service as the core, customer experience as the feature, digital marketing as the support, and offline distribution as the basis. With professional services such as cold chain management, it not only meets the needs of patients with different types of drugs, but also provides patients with professional health management services. It is reported that the first prescription of Astellas’s new prostate cancer drug XOSPATA® approved in China was also placed in Baheal Health Pharmacy.

Baheal Medical has always been adhering to the mission of providing better medical and health products and services for the whole society, and strives to build a professional brand commercialization platform in the downstream of the pharmaceutical industry chain. With category insight-based brand operation, Baheal Data Platform customer management and long-term operation mechanisms of the three capabilities as the core, it provides omni-channel solutions for upstream industrial enterprises.

At present, in addition to Astellas, Baheal Medical has reached in-depth cooperation with well-known pharmaceutical companies such as Roche Pharmaceuticals, Xi'an Janssen, Takeda Pharmaceuticals, and CSL Behring. Through professional brand commercialization platforms, Baheal Medical helps partners integrate products, technologies and services to develop to a wider market, quickly enter the application scene, fully release the market value, and jointly bring more abundant medicines and more professional and high-quality services to patients.